Anti-Scl-70 refers to autoantibodies directed against topoisomerase I, an enzyme involved in DNA replication and repair, commonly associated with systemic sclerosis (scleroderma). Their presence is significant in clinical practice as it helps in diagnosing and predicting disease severity, particularly in diffuse scleroderma, which can lead to serious complications such as pulmonary fibrosis and renal crisis. Monitoring these antibodies aids in assessing disease progression and treatment response.